Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Lawrence J. Jasinski BS, MBA | CEO & Director | 473.27k | -- | 1957 |
Mr. Charles Remsberg | Chief Sales Officer | 375k | -- | 1962 |
Ms. Jeannine Lynch | Vice President of Market Access & Strategy | 369k | -- | 1966 |
Mr. Michael A. Lawless | Chief Financial Officer | 418.41k | -- | 1969 |
Ms. Miri Pariente | Vice President of Operations, Regulatory & Quality | 337.81k | -- | 1977 |
Mr. Almog Adar | VP of Finance & Chief Accounting Officer | 263.62k | -- | 1985 |
Ms. Judy Kula | Vice President of Customer Service, Human Resources & Business Affairs | -- | -- | -- |
Lifeward Ltd.
- Sector:
- Healthcare
- Industry: Medical Devices
- Full Time Employees:
- 80
Description
Lifeward Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals' post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as ReWalk Robotics Ltd. and changed its name to Lifeward Ltd. in September 2024. Lifeward Ltd. was incorporated in 2001 and is based in Yokneam Illit, Israel.
Corporate Governance
Upcoming Events
May 13, 2025 at 12:30 PM UTC - May 19, 2025 at 12:30 PM UTC
Lifeward Ltd. Earnings Date
Recent Events
February 14, 2025 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission